BACKGROUND: Irritable bowel syndrome (IBS) is a chronic and debilitating functional gastrointestinal disorder affecting 9%-23% of the population across the world. The relative efficacy of fecal microbiota transplantation (FMT) on IBS symptoms was demonstrated in a double-blind, randomized study. METHODS: We describe the case of a 73-year-old woman suffering from IBS (abdominal pain, bloating, and abundant and disabling diarrhea, with 10-15 stools a day) and repetitive urinary tract infection (UTI; 5 episodes in 6 months, including 3 the last 2 months) for several years, generating an impaired quality of life. She received an FMT with 400 mL of fecal infusion from a healthy donor via a nasogastric tube after bowel lavage. Her digestive microbiota was analyzed using culturomic and metagenomic targeting 16S rRNA sequencing methods. RESULTS: Eight months after transplantation, we observed a significant reduction in frequency and improvement in stool consistency (3-4 molded stools a day against 10-15 before the transplant) and no recurrence of urinary infection (as previously reported). Using culturomics, we found 12 bacteria present in the fecal infusion and post-transplant stool; these were absent pretransplant. Three of them (Intestinimonas massiliensis, Oscillibacter massiliensis, and Provencibacter massiliensis) were previously discovered and cultivated in our laboratory using culturomics. Using metagenomics, we also observed 12 bacteria, different from those observed during culture, that could have been transferred to the patient by FMT. CONCLUSIONS: In this case report, IBS symptoms and UTI frequency decreased after FMT UTI. Further studies involving more patients would be relevant to confirm this work and develop bacteriotherapy.
BACKGROUND: Irritable bowel syndrome (IBS) is a chronic and debilitating functional gastrointestinal disorder affecting 9%-23% of the population across the world. The relative efficacy of fecal microbiota transplantation (FMT) on IBS symptoms was demonstrated in a double-blind, randomized study. METHODS: We describe the case of a 73-year-old woman suffering from IBS (abdominal pain, bloating, and abundant and disabling diarrhea, with 10-15 stools a day) and repetitive urinary tract infection (UTI; 5 episodes in 6 months, including 3 the last 2 months) for several years, generating an impaired quality of life. She received an FMT with 400 mL of fecal infusion from a healthy donor via a nasogastric tube after bowel lavage. Her digestive microbiota was analyzed using culturomic and metagenomic targeting 16S rRNA sequencing methods. RESULTS: Eight months after transplantation, we observed a significant reduction in frequency and improvement in stool consistency (3-4 molded stools a day against 10-15 before the transplant) and no recurrence of urinary infection (as previously reported). Using culturomics, we found 12 bacteria present in the fecal infusion and post-transplant stool; these were absent pretransplant. Three of them (Intestinimonas massiliensis, Oscillibacter massiliensis, and Provencibacter massiliensis) were previously discovered and cultivated in our laboratory using culturomics. Using metagenomics, we also observed 12 bacteria, different from those observed during culture, that could have been transferred to the patient by FMT. CONCLUSIONS: In this case report, IBS symptoms and UTI frequency decreased after FMT UTI. Further studies involving more patients would be relevant to confirm this work and develop bacteriotherapy.
Authors: J-C Lagier; F Armougom; M Million; P Hugon; I Pagnier; C Robert; F Bittar; G Fournous; G Gimenez; M Maraninchi; J-F Trape; E V Koonin; B La Scola; D Raoult Journal: Clin Microbiol Infect Date: 2012-10-03 Impact factor: 8.067
Authors: Ian B Jeffery; Paul W O'Toole; Lena Öhman; Marcus J Claesson; Jennifer Deane; Eamonn M M Quigley; Magnus Simrén Journal: Gut Date: 2011-12-16 Impact factor: 23.059
Authors: J-C Lagier; M Delord; M Million; P Parola; A Stein; P Brouqui; D Raoult Journal: Eur J Clin Microbiol Infect Dis Date: 2015-05-07 Impact factor: 3.267
Authors: Mirjana Rajilić-Stojanović; Elena Biagi; Hans G H J Heilig; Kajsa Kajander; Riina A Kekkonen; Sebastian Tims; Willem M de Vos Journal: Gastroenterology Date: 2011-08-05 Impact factor: 22.682
Authors: Thorsten Stoeck; Anke Behnke; Richard Christen; Linda Amaral-Zettler; Maria J Rodriguez-Mora; Andrei Chistoserdov; William Orsi; Virginia P Edgcomb Journal: BMC Biol Date: 2009-11-03 Impact factor: 7.431
Authors: Marta Pozuelo; Suchita Panda; Alba Santiago; Sara Mendez; Anna Accarino; Javier Santos; Francisco Guarner; Fernando Azpiroz; Chaysavanh Manichanh Journal: Sci Rep Date: 2015-08-04 Impact factor: 4.379
Authors: Kait F Al; John D Denstedt; Brendan A Daisley; Jennifer Bjazevic; Blayne K Welk; Stephen E Pautler; Gregory B Gloor; Gregor Reid; Hassan Razvi; Jeremy P Burton Journal: Cell Rep Med Date: 2020-09-22
Authors: Matthew Magruder; Emmanuel Edusei; Lisa Zhang; Shady Albakry; Michael J Satlin; Lars F Westblade; Line Malha; Christina Sze; Michelle Lubetzky; Darshana M Dadhania; John R Lee Journal: Gut Microbes Date: 2020-11-09
Authors: Bernadette Jones-Freeman; Michelle Chonwerawong; Vanessa R Marcelino; Aniruddh V Deshpande; Samuel C Forster; Malcolm R Starkey Journal: Mucosal Immunol Date: 2021-02-04 Impact factor: 7.313
Authors: T Schiereck; S Yeldan; J Kranz; L Schneidewind; F Wagenlehner; I Wieters; M J G T Vehreschild; T Otto; D Barski Journal: Urologe A Date: 2021-08-23 Impact factor: 0.639
Authors: Karuna E W Vendrik; Tim G J de Meij; Arend Bökenkamp; Rogier E Ooijevaar; Bas Groenewegen; Antoni P A Hendrickx; Elisabeth M Terveer; Ed J Kuijper; Joffrey van Prehn Journal: Open Forum Infect Dis Date: 2022-06-29 Impact factor: 4.423
Authors: Max W Adelman; Michael H Woodworth; Virginia O Shaffer; Greg S Martin; Colleen S Kraft Journal: Crit Care Med Date: 2021-01-01 Impact factor: 9.296